Bright Minds Biosciences Inc (DRUG) - Total Assets
Based on the latest financial reports, Bright Minds Biosciences Inc (DRUG) holds total assets worth $312.15 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Bright Minds Biosciences Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.
Bright Minds Biosciences Inc - Total Assets Trend (2019–2025)
This chart illustrates how Bright Minds Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See what is Bright Minds Biosciences Inc's book value for net asset value and shareholders' equity analysis.
Bright Minds Biosciences Inc - Asset Composition Analysis
Current Asset Composition (September 2025)
Bright Minds Biosciences Inc's total assets of $312.15 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 98.2% |
| Accounts Receivable | $413.07K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Bright Minds Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see DRUG market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bright Minds Biosciences Inc's current assets represent 99.9% of total assets in 2025, an increase from 48.8% in 2019.
- Cash Position: Cash and equivalents constituted 98.2% of total assets in 2025, up from 48.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Bright Minds Biosciences Inc Competitors by Total Assets
Key competitors of Bright Minds Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Bright Minds Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 81.48 | 88.27 | 68.80 |
| Quick Ratio | 81.48 | 88.27 | 68.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $308.24 Million | $55.68 Million | $21.89 Million |
Bright Minds Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Bright Minds Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.73 |
| Latest Market Cap to Assets Ratio | 7.16 |
| Asset Growth Rate (YoY) | 1282.9% |
| Total Assets | $84.42 Million |
| Market Capitalization | $604.13 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Bright Minds Biosciences Inc's assets at a significant premium (7.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Bright Minds Biosciences Inc's assets grew by 1282.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bright Minds Biosciences Inc (2019–2025)
The table below shows the annual total assets of Bright Minds Biosciences Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $84.42 Million | +1282.92% |
| 2024-09-30 | $6.10 Million | -11.26% |
| 2023-09-30 | $6.88 Million | -43.09% |
| 2022-09-30 | $12.09 Million | -39.69% |
| 2021-09-30 | $20.04 Million | +2176.76% |
| 2020-09-30 | $880.22K | +436.81% |
| 2019-09-30 | $163.97K | -- |
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more